Taliglucerase alfa is an enzyme replacement therapy approved for Gaucher disease. We assessed the duration/compliance/safety of such home infusions in commercial use in four countries where home infusion programs are available. The treatment duration/compliance study included 173 patients (Israel, 58; US, 61; Brazil, 48; Australia, 6) who received ≥1 taliglucerase alfa home infusion through 6/2021. The median age at home therapy initiation was 38 (range, 2–87) years; 58% were females. The median treatment duration (at home) was 2.7 (range, 0.04–9.0) years. The annual compliance rate was stable (≥95%) throughout the study period. A search of the Pfizer global safety database (through 6/2021), identified 19 adverse events (AEs) as related to “definite home use” and 14 to “possible home use” of taliglucerase alfa; 42.4% of these AEs were serious; none were fatal. Twelve serious AEs in five separate case reports were considered treatment related: one case of chest discomfort/pain and hypertension and one case of erythema associated with a toe blister, for which causality could not be excluded; pain in extremity; projectile vomiting and chills, alongside excessive eye blinking; and an infusion-related AE (pruritus). In conclusion, this real-life global study demonstrated that taliglucerase alfa home infusions are safe with high compliance rates.
Background: Despite the availability of effective therapies for Gaucher disease (GD), management of skeletal disease manifestations remains challenging. Methods: This phase 4 SHP-GCB-402 study evaluated the effect of velaglucerase alfa on lumbar spine (LS) bone outcomes in patients with type 1 GD. Results: Twenty-one patients with documented bone pathology received ≥1 dose of velaglucerase alfa 60 U/kg; 16 completed this study. The primary endpoint—change from baseline to 24 months in an LS bone mineral density (BMD) Z-score measured by dual-energy X-ray absorptiometry—showed a numerical improvement from baseline (mean [SD] −1.93 [0.88]) to 24 months (−1.76 [1.00]), although statistical significance was not reached (p = 0.1077). These changes are not consistent with previous velaglucerase alfa studies. To contextualize these findings, a pooled analysis of 24-month data from previous velaglucerase alfa trials was conducted. In this cohort (n = 40), a statistically significant mean (SD) increase in the LS BMD Z-score of 0.55 (0.58; p < 0.0001) was observed, supporting the therapeutic potential of velaglucerase alfa in improving skeletal outcomes. Additionally, SHP-GCB-402 demonstrated a significant reduction in the bone marrow burden (BMB) score (mean change from baseline: −3.0 [2.27]; p = 0.0005), indicating a positive effect on bone marrow infiltration. All patients experienced ≥1 treatment-emergent adverse event, mostly of mild/moderate severity. Conclusions: The observed numerical improvements in BMD and significant improvements in BMB in SHP-GCB-402 along with pooled BMD data suggest that velaglucerase alfa may confer skeletal benefits while maintaining a consistent safety profile.